Nature Clinical Practice Nephrology
Technology Insight: Biomarker Development In Acute Kidney Injury -- What Can We Anticipate? CME

Disclosures

Release Date: January 29, 2008; Valid for credit through January 29, 2009
Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

Contents of This CME Activity
    The content of this CME activity, "Technology Insight: Biomarker Development In Acute Kidney Injury -- What Can We Anticipate?," was developed by the faculty.

    To participate in this activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

    Acute kidney injury (AKI) is associated with significant morbidity and mortality, but currently available biomarkers for predicting which patients will develop AKI and suffer from poor outcomes are flawed. The current review examines these biomarkers and suggests future directions for translational research in regard to this important subject.

  1. Technology Insight: Biomarker Development In Acute Kidney Injury -- What Can We Anticipate?
    Bruce A. Molitoris, MD
    Vyacheslav Y. Melnikov, MD
    Mark D. Okusa, MD
    Jonathan Himmelfarb, MD

Go to Test Questions

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 Medscape.

 
WebMD
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. List characteristics of a good biomarker
  2. Specify clinical risk factors for acute kidney injury (AKI) after cardiac surgery
  3. Describe limitations of biomarkers for the surveillance of AKI
  4. Identify new biomarkers that may help predict outcomes of AKI
Authors and Disclosures

Bruce A. Molitoris, MD
Disclosure: Bruce A. Molitoris, MD, has disclosed no relevant financial relationships.


Vyacheslav Y. Melnikov, MD
Disclosure: Vyacheslav Y. Melnikov, MD, has disclosed no relevant financial relationships.


Mark D. Okusa, MD
Disclosure: Mark D. Okusa, MD, has disclosed no relevant financial relationships.


Jonathan Himmelfarb, MD
Disclosure: Jonathan Himmelfarb, MD, has disclosed no relevant financial relationships.


Charles P. Vega, MD
Disclosure: Charles P. Vega, MD, has disclosed that he has served as an advisor or consultant to Novartis, Inc.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.